News & Updates
Filter by Specialty:
Real-world study supports tralokinumab for difficult-to-treat AD
Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.
Real-world study supports tralokinumab for difficult-to-treat AD
18 Oct 2024
Antipsychotic resistance tied to poorer cognitive function in schizophrenia
Resistance to antipsychotic treatment may result in worse cognitive function among patients with schizophrenia, with disorganization, doses, and negative symptoms playing a major role in this association, according to a Singapore study.
Antipsychotic resistance tied to poorer cognitive function in schizophrenia
17 Oct 2024
Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB
In the treatment of patients with rifampicin-resistant tuberculosis (TB), two bedaquiline-containing regimens, namely a 9-month all-oral regimen and a shorter 6-month regimen with 8 weeks of aminoglycoside, maintains superior efficacy to a 9-month injectable regimen through 132 weeks, according to long-term data from the STREAM 2 trial.
